Measurement of individual angiotensin peptides by HPLC-RIA. 1990

M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
Department of Obstetrics, University of Leuven, Belgium.

Immunoreactive measurements of Angiotensin II in plasma, relate to a variety of angiotensin peptides with different biological activities. A method is described to differentiate these individual angiotensin peptides. It involves extraction of the peptides from plasma by reversible adsorption to phenylsilyl silica cartridges, separation by an isocratic, ion pairing high-pressure liquid chromatography technique and measurement of the appropriate fractions by radioimmunoassay. In umbilical venous plasma molar concentrations of the smaller angiotensin fragments were found to range between 16 and 25% of the concentrations of the angiotensin II octapeptide. Because some angiotensin antisera show higher affinity for the smaller peptides than for the octapeptide, concentrations of angiotensin II, measured by radioimmunoassay, may be overestimated by up to 35% unless the various angiotensin peptides are adequately separated.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
January 2017, Methods in molecular biology (Clifton, N.J.),
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
April 1994, Prostaglandins,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
June 1990, Transplantation proceedings,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
August 1982, Brain research,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
January 1984, Peptides,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
June 1988, Clinical chemistry,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
January 1979, Veterinary and human toxicology,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
April 1987, American journal of clinical pathology,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
January 1988, Peptides,
M Hanssens, and M J Keirse, and P J Lijnen, and M J Kucharski, and C Luyten, and F A Van Assche
January 2017, Methods in molecular biology (Clifton, N.J.),
Copied contents to your clipboard!